AAA817

PreclinicalSmall molecule

Novartis

AAA817 is one of 16 small molecule programs targeting Targeted Therapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Targeted TherapyRecruiting

Targeted TherapyPreclinical

Recruiting

Competition

Competitive Landscape

18 competitors in Targeted Therapy

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

2 2

Xospata

Astellas

Phase 3

2 3

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 4

Tafinlar

Novartis

Phase 2

1 5

Gazyva

Roche

Phase 2

1 6

Fasenra

AstraZeneca

Phase 2

1 7

Opdivo

Bristol-Myers Squibb

Phase 2

1 8

Braftovi

Pfizer

Phase 2

1 9

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 10

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 3Recruiting

Prostate Cancer

NCT06855277

Q3 2033

PreclinicalRecruiting

Prostate Cancer

NCT06780670

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer

Recruiting· Novartis logo

Novartis·Phase 3·NCT06855277·940 enrolled

PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Recruiting· Novartis logo

Novartis·Preclinical·NCT06780670·443 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AAA817. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AAA817 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AAA817. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novartis

AAA817

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Q3 2033

Trials by Indication[1]

Prostate Cancer2 trials

References

Drug Info

Quick Facts

Related News